Your browser doesn't support javascript.
loading
Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25].
Chau, Ian; Peck-Radosavljevic, Markus; Borg, Christophe; Malfertheiner, Peter; Seitz, Jean Francois; Park, Joon Oh; Ryoo, Baek-Yeol; Yen, Chia-Jui; Kudo, Masatoshi; Poon, Ronnie; Pastorelli, Davide; Blanc, Jean-Frederic; Chung, Hyun Cheol; Baron, Ari D; Okusaka, Takuji; Bowman, L; Cui, Zhanglin Lin; Girvan, Allicia C; Abada, Paolo B; Yang, Ling; Zhu, Andrew X.
Afiliação
  • Chau I; Royal Marsden Hospital, London and Surrey, United Kingdom. Electronic address: ian.chau@rmh.nhs.uk.
  • Peck-Radosavljevic M; Allgemeines Krankenhaus Wien, Vienna and Klinkum Klagenfurt am Wörthersee, Klagenfurt, Austria.
  • Borg C; Hospital Jean Minjoz, Besançon, France.
  • Malfertheiner P; Universitätsklinikum Magdeburg, Magdeburg, Germany.
  • Seitz JF; Hôpital La Timone, Aix-Marseille University, Marseille, France.
  • Park JO; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Ryoo BY; Asan Medical Center, Seoul, Republic of Korea.
  • Yen CJ; National Cheng Kung University Hospital, Tainan, Taiwan.
  • Kudo M; Kinki University School of Medicine, Osaka-Sayama, Osaka, Japan.
  • Poon R; The University of Hong Kong, Hong Kong.
  • Pastorelli D; Istituto Oncologico Veneto IRCCS, Padova, Italy.
  • Blanc JF; Hepato-Gastroenterology and Digestive Oncology Unit, Centre Medico-chirurgical Magellan, CHU Bordeaux, France.
  • Chung HC; Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea.
  • Baron AD; Sutter Health California Pacific Medical Center, San Francisco, CA, USA.
  • Okusaka T; National Cancer Center Hospital, Tokyo, Japan.
  • Bowman L; Eli Lilly and Company, Indianapolis, IN, USA.
  • Cui ZL; Eli Lilly and Company, Indianapolis, IN, USA.
  • Girvan AC; Eli Lilly and Company, Indianapolis, IN, USA.
  • Abada PB; Eli Lilly and Company, Indianapolis, IN, USA.
  • Yang L; Eli Lilly and Company, Bridgewater, NJ, USA.
  • Zhu AX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Eur J Cancer ; 100: 135-136, 2018 09.
Article em En | MEDLINE | ID: mdl-29970352
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Eur J Cancer Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Eur J Cancer Ano de publicação: 2018 Tipo de documento: Article